<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Efficacy and safety of current means to prevent cerebrovascular <z:mp ids='MP_0005048'>thrombosis</z:mp> in patients at high risk of <z:hpo ids='HP_0001297'>stroke</z:hpo> are suboptimal </plain></SENT>
<SENT sid="1" pm="."><plain>In theory, anchoring fibrinolytic plasminogen activators to the <z:chebi fb="2" ids="8069">luminal</z:chebi> surface of the cerebral endothelium might arrest formation of occlusive clots in this setting </plain></SENT>
<SENT sid="2" pm="."><plain>We tested this approach using the recombinant construct antiplatelet-endothelial cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule (PECAM) single-chain variable fragment (scFv)-urokinase-type plasminogen activator (uPA), fusing low-molecular-weight single-chain urokinase-type plasminogen activator with a scFv of an antibody directed to the stably expressed endothelial surface determinant PECAM-1, implicated in <z:mp ids='MP_0001845'>inflammation</z:mp> and <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Studies in mice showed that scFv-uPA, but not unconjugated uPA 1) accumulates in the brain after intravascular injection, 2) lyses clots lodged in the cerebral arterial vasculature without hemorrhagic complications, 3) provides rapid and stable cerebral reperfusion, and 4) alleviates post-thrombotic <z:hpo ids='HP_0002181'>brain edema</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Effective and safe thromboprophylaxis in the cerebral arterial circulation by anti-PECAM scFv-uPA represents a prototype of a new paradigm to prevent recurrent cerebrovascular <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
</text></document>